Schiffman M, Adrianza M E
National Cancer Institute, Bethesda, Maryland 20852, USA.
Acta Cytol. 2000 Sep-Oct;44(5):726-42. doi: 10.1159/000328554.
To describe the design and methods of the ASCUS-LSIL Triage Study (ALTS), a multicenter, randomized clinical trial designed to evaluate three alternative methods of managing low grade (LSIL) and equivocal (ASCUS) cervical cytologic diagnoses.
Nonpregnant women, 18+ years old, with ASCUS or LSIL, no prior hysterectomy or ablative therapy to the cervix, were referred to one of four clinical centers around the United States. Eligible and consenting participants were administered a risk-factor questionnaire and underwent a pelvic examination, collection of cervical specimens for liquid-based cytology and human papillomavirus (HPV) testing and Cervicography (National Testing Laboratories, Fenton, Missouri, U.S.A.). Patients were randomized to one of three arms: (1) immediate referral for colposcopy at enrollment, (2) follow-up with cytology only, and (3) use of HPV DNA testing to triage to colposcopy. All women are followed every six months for two years with pelvic examinations, cytologic and masked HPV testing, and masked Cervicography. Digital cervical images and cytology and histology slides are externally reviewed to maximize patient safety.
We enrolled and randomized 3,488 eligible women with ASCUS and 1,572 women with LSIL.
The successful enrollment, randomization and high rates of follow-up are encouraging. The study will help clarify the optimal strategies for managing low grade cervical abnormalities.
描述非典型鳞状细胞意义不明确(ASCUS)/低度鳞状上皮内病变(LSIL)分流研究(ALTS)的设计和方法,这是一项多中心随机临床试验,旨在评估三种处理低度(LSIL)和意义不明确(ASCUS)宫颈细胞学诊断的替代方法。
年龄18岁及以上、患有ASCUS或LSIL、未曾接受过子宫切除术或宫颈消融治疗的非妊娠女性被转介到美国四个临床中心之一。符合条件并同意参与的受试者接受了风险因素问卷调查,并接受了盆腔检查、收集宫颈标本进行液基细胞学检查和人乳头瘤病毒(HPV)检测以及宫颈造影检查(美国密苏里州芬顿市国家检测实验室)。患者被随机分为三组之一:(1)入组时立即转诊进行阴道镜检查;(2)仅进行细胞学随访;(3)使用HPV DNA检测分流至阴道镜检查。所有女性每六个月接受为期两年的随访,包括盆腔检查、细胞学和盲法HPV检测以及盲法宫颈造影检查。对数字化宫颈图像以及细胞学和组织学切片进行外部评估,以最大限度地保障患者安全。
我们招募并随机分配了3488名符合条件的ASCUS女性和1572名LSIL女性。
成功的入组、随机分组和高随访率令人鼓舞。该研究将有助于明确处理低度宫颈异常的最佳策略。